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Abstract
Background/Aim. Sometimes resistance of Pseudomonas
aeruginosa (Ps. aeruginosa) is developed during antibiotic treat-
ment, in spite of the initial susceptibility in vitro. The aim of
this study was to use an in vitro model for the study of the de-
velopment of resistant strains of Ps. aeruginosa after a short
exposure to ceftazidime, and to study the hydrolysing capac-
ity of β-lactamases produced by the resistant strains. Meth-
ods. Among 563 clinical strains of Ps. aeruginosa, 37 multisen-
sitive strains were collected for the study. After being identi-
fied, strains with simultaneous sensitivity to 5 expanded
spectrum cephalosporins were chosen. For each strain, the
minimal inhibitory concentration (MIC) of the 5 expanded
spectrum cephalosporins was determined, and the production
of extended spectrum β-lactamases (ESBL) was excluded by
the double-disc synergy diffusion test. Strains non producing
ESBL were cultivated in concentrations of ceftazidime equal
to MIC×2 and MIC×4. After 24 hours of culture, the devel-
opment of resistant strains was estimated and the cephalo-
sporinase activity of the produced β-lactamases was deter-
mined by their ability to hydrolyse cefazolin. Hydrolysis of
cefazolin was studied by measuring the change of its absorb-
ance on 272 nm using a Shimadzu 160A spectrophotometer.
The hydrolyzing capacity of the enzymes was expressed as
the percentage of the antibiotic, which was hydrolysed in 10
sec. Results. A total of 60% and 50% of strains developed
resistant strains after exposure to ceftazidime in concentra-
tion MIC×2 and MIC×4, respectively. The hydrolyzing ca-
pacity of the original strains was 15-36% while the hydrolyz-
ing capacity of the resistant strains was 10-73%. Totally 64%
of the resistant strains expressed higher hydrolyzing capacity
than the original strains. Conclusion. Regardless of the sus-
ceptibility test results, Ps. aeruginosa presented a high tendency
to develop resistant strains after a short exposure to ceftazi-
dime  in vitro. In most cases the resistant strains expressed
higher cephalosporinase activity than the original strains, sug-
gesting derepression of chromosomal β-lactamases. Our
model offers a simple, inexpensive and rapid method for de-
tecting resistance of Ps. aeruginosa developed due to derepres-
sion of β-lactamases, and for discriminating resistant strains
with derepressed β-lactamases from strains that developed
other mechanisms of resistance.
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Apstrakt
Uvod/Cilj. Tokom primene antibiotika ponekad dolazi do
razvoja rezistencije Pseudomonas aeruginosa (Ps. aeruginosa) na
njih bez obzira na početnu osetljivost in vitro. Cilj ove studije
bio je da se primenom in vitro modela utvrdi razvijanje rezi-
stentnog soja Ps. aeruginosa posle kratkog izlaganja ceftazidi-
mu, kao i da se odredi hidrolitička aktivnost  β-laktamaza
koje proizvode rezistentni sojevi. Metode. Od 563 klinička
soja Ps. aeruginosa za ovu studiju izdvojeno je 37 multisenzi-
tivnih sojeva. Posle identifikacije, izdvojeni su sojevi istov-
remeno osetljivi na pet cefalosporina proširenog spektra. Za
svaki soj izvršeno je određivanje minimalne inhibitorne
koncentracije (MIC) pet cefalosporina. Sojevi koji ne pro-
dukuju β-laktamaze proširenog spektra (ESBL) određeni su
pomoću double-disc synergy diffusion testa. Oni sojevi koji nisu
proizvodili ESBL kultivisani su u prisustvu ceftazidima u
koncentracijama koje su odgovarale MIC×2 i MIC×4. Posle
24 sata kultivisanja određeno je razvijanje rezistentnih soje-
va i cefalosporinazna aktivnost produkovanih β-laktamaza
na osnovu njihove sposobnosti da hidrolizuju cefazolin. Hi-
droliza cefazolina određena je merenjem njegove absorban-
ce na 272 nm primenom spektrofotometra Shimadzu 160A.
Hidrolizujući kapacitet enzima izražen je u procentima anti-
biotika hidrolizovanog tokom 10 sec. Rezultati. Ukupno
60% sojeva razvilo je rezistentne sojeve posle izlaganja cef-
tazidimu u koncentraciji MIC×2, dok je 50% sojeva razvilo
rezistentne sojeve posle izlaganja antibiotiku u koncentracijiStrana 786 VOJNOSANITETSKI PREGLED Volumen 66, Broj 10
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MIC×4. Hidrolizujući kapacitet originalnih sojeva bio je 15–
36%, a rezistentnih sojeva 10–73%. Ukupno 64% rezistent-
nih sojeva pokazalo je veći hidrolizujući kapacitet od origi-
nalnih sojeva. Zaključak. Bez obzira na rezultate testiranja
osetljivosti, bakterija Ps. aeruginosa pokazala je visoku sklo-
nost ka razvijanju rezistentnih sojeva posle kratkog in vitro
izlaganja ceftazidimu. U većini slučajeva rezistentni sojevi
pokazali su veću cefalosporinaznu aktivnost od originalnih
sojeva, što ukazuje na derepresiju β-laktamaza. Prikazana
metoda predstavlja  jednostavan, jeftin i brz način određiva-
nja rezistencije Ps. aeruginosa nastale usled derepresije β-
laktamaza, kao i diskriminacije mutanata sa β-laktamazama
od mutanata koji razvijaju druge mehanizme rezistencije.
Ključne reči:
lekovi, rezistencija mikroorganizama; antibiotici;
cefalosporini; cefazolin; ceftazidim; pseudomonas
aeruginosa.
Introduction
Clinical experience has shown that microbial resistance
to antibiotics is sometimes developed during antibiotic ther-
apy, in spite of the initial susceptibility of microbial patho-
gens before treatment 
1. This is observed very often in clini-
cal strains of Pseudomonas aeruginosa (Ps. aeruginosa), an
opportunistic pathogen involved in hospital infections. Ps.
aeruginosa infections are common in patients with compro-
mised immune system or chronic infections, and in patients
treated in Intensive Care Units (ICU) 
2–4. Development of re-
sistant strains of Ps. aeruginosa during antimicrobial therapy
is a frequent problem with major clinical consequences in
ICU, often resulting in therapeutic failure 
5, 6.
Outbreaks of infection with strains of Enterobacteria-
ceae producing extended spectrum beta-lactamases (ESBL)
revealed the necessity for screening for ESBL production, as
strains producing ESBL may be found susceptible in anti-
biograms and appear resistant during antibiotic treatment 
1, 7.
Although strains of Ps. aeruginosa producing ESBL have
been reported to occur in Greek hospitals 
8–13, the most
common mechanism for development of resistance to β-
lactams is selection of mutations leading to hyperproduction
of the chromosomal AmpC β-lactamase  
6, 14, 15. The activity
of the antipseudomonal penicillins and cephalosporins
against  Ps. aeruginosa is based on the fact that although
these compounds are certainly hydrolyzed by AmpC, they
are very weak inducers of this chromosomal β-lactamase 
6, 16.
Nevertheless, during treatment with β-lactams, resistant mu-
tants showing high levels of AmpC production are frequently
selected, leading to therapeutic failure 
16, 17. Although there
are modified double-disk tests for the detection of Entero-
bacteriaceae producing basal AmpC β-lactamases 
7, there
are no recommendations for the routine detection of these
enzymes in Ps. aeruginosa.
The purpose of this study was to use an in vitro model
for the study of the development of resistant strains of Ps.
aeruginosa due to AmpC β-lactamases partially or stably
derepressed, after a short exposure to ceftazidime, and to
study the hydrolysing capacity of β-lactamases produced by
the resistant strains. Ceftazidime was chosen because it is a
3rd generation cephalosporin with special activity against Ps.
aeruginosa, and it is commonly used to treat pseudomonal
infections. The tendency of Pseudomonas to develop resis-
tant strains to ceftazidime in vitro, reflects a similar effect in
vivo, which may lead to therapeutic failure in immunocom-
promised patients.
Methods
A total of 563 clinical strains of Ps. aeruginosa were
collected from clinical specimens in the AHEPA General
Hospital, Thessaloniki, Greece, and Agios Loukas General
Hospital, Thessaloniki, Greece. The isolates were non repeti-
tive (one per patient). All multisensitive strains, which showed
sensitivity to β-lactams, aminoglycosides and quinolones were
chosen for the study. After being identified with Vitek I
(bioMerieux) and confirmed by the agar dilution method in
Iso-Sensitest agar medium (Oxoid, Basingstoke, UK), strains
with simultaneous sensitivity to the following expanded spec-
trum cephalosporins: ceftazidime, cefotaxime, ceftriaxone, ce-
fixime, cefepime, were collected for the study:
The following commercial forms of cephalosporins
were used: ceftazidime (SOLVETAN, Glaxo Wellcome,
dr.pd.inj. 1g/vial), cefotaxime (CLAFORAN, Hoechst Mar-
ion Roussel, dr.pd.inj. 1g/vial), ceftriaxone (ROCEPHIN,
Roche, dr.pd.inj. 1g/vial), cefixime (CEFTORAL, Vianex,
coated tablets 400  mg), cefepime (MAXIPIME, Bristol
Myers Squibb, dr.pd.inj. 1g/vial), cefazolin (KEFZOL,
Pharmaserve Lilly, dr.pd.inj. 1g/vial).
The Iso-Sensitest agar medium (Oxoid, Basingstoke,
UK) was used for microbial cultures.
The susceptibility of the isolates to antibiotics was de-
termined by the automated identification system Vitek I
(bioMerieux) and was confirmed by the agar dilution method
in Iso-Sensitest agar medium (Oxoid, Basingstoke, UK).
Susceptibility tests were performed and interpreted according
to the recommendations of the British Society for Antimi-
crobial Chemotherapy (BSAC) 
18, 19. For each strain, the
minimal inhibitory concentration (MIC) of the 5 expanded
spectrum cephalosporins was determined, and the production
of ESBL was excluded by the double-disc synergy diffusion
test (DDST) 
6, 16.
Strains with simultaneous sensitivity to the 5 expanded
spectrum  β-lactams  were suspended in distilled water, ad-
justed to a 0.5 McFarland standard and diluted in distilled
water (1:100), to obtain a suspension containing 10
6 cfu/mL.
A sterile cotton-wool swab was dipped into the suspension
and the inoculum was spread evenly over the entire surface
of plates containing Iso-Sensitest agar medium and ceftazi-
dime in concentrations equal to MIC×2 and MIC×4. The
plates were incubated at 37  °C for 24 hours, and were
checked for the development of resistant strains.
β-lactamases produced by the original and the resistant
strains were separated from microbial cells and their cepha-Volumen 66, Broj 10 VOJNOSANITETSKI PREGLED Strana 787
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losporinase activity was tested by their ability to hydrolyse
cefazolin. Hydrolysis of cefazolin was studied by measuring
the change of its absorbance in 272 nm, using a Shimadzu
160A spectrophotometer, as described in the British Pharma-
copoeia 
20. The hydrolysing capacity of the enzymes was ex-
pressed as the percentage of the antibiotic which was hydro-
lysed in 10 sec.
Results
Out of 563 collected clinical strains of Ps. aeruginosa,
37 strains showed sensitivity to β-lactams, aminoglycosides
and quinolones. From these multisensitive strains, ten strains
showed simultaneous sensitivity to the expanded spectrum
cephalosporins (ceftazidime, cefotaxime, ceftriaxone, ce-
fixime, cefepime), confirmed by determination of the relative
MICs. The production of ESBL was further excluded by the
DDST. The MIC of ceftazidime for each of these strains
ranged from 0.5 to 1.0 μg/mL.
After culture in the presence of ceftazidime in concen-
trations equal to MIC×2 and MIC×4, eleven resistant strains
were developed: six out of ten strains developed resistant
strains in the presence of a concentration of ceftazidime
equal to MIC×2 (60%) and five out of ten strains developed
resistant strains in the presence of a concentration of ceftazi-
dime equal to MIC×4 (50%).
Hydrolysis of cefazolin by the enzymes produced by
the original and the resistant strains of Ps. aeruginosa is pre-
sented in Figure 1. The hydrolyzing capacity of the original
strains was 15–36% while the hydrolyzing capacity of the re-
sistant strains was 10-73%. Seven out of eleven resistant
strains (64%) presented a higher hydrolysing capacity than
original strains and four out of eleven mutant strains (36%)
presented a lower hydrolysing capacity than original strains
(Table 1).
Discussion
Development of resistance to the antipseudomonal peni-
cillins and cephalosporins, mediated by hyperproduction of the
chromosomal cephalosporinase AmpC, is a major problem in
the treatment of Ps. aeruginosa infections 
15. Inducible AmpC
β-lactamases (AmpC) can be upregulated by subinhibitory
concentrations of certain β-lactam antibiotics 
6, 21, 22. Further,
mutations can occur in the regulatory components of AmpC
leading to a stable hyperproduction of AmpC with concomi-
tant high-level resistance to many classes of β-lactam antibi-
otics 
22, 23. Induction is a transient phenotypic response to a β-
lactam; stably-derepression, on the other hand, is the perma-
nent hyperproduction of the enzyme, regardless of antibiotic
presence. Derepression may be partial, such that the organism
produces an unusually high uninduced level of enzyme but
retains inducibility, or total, such that β-1actamase expression
is constitutive (i.e. entirely unregulated by antibiotic presence)
14, 24. Stably derepressed mutants occur at frequencies from 10
-5
to 10
-8 in β-1actamase inducible populations 
25–27.
In our study we investigated in vitro development of re-
sistant strains of Ps. aeruginosa, due to derepressed AmpC β-
lactamases after exposure to ceftazidime in concentrations
much higher than MIC (MIC×2 and MIC×4). A double
screening test was used for the collection of strains, in order to
exclude the production of ESBL: phenotype and DDST 
16.
Thus, the collected strains produced only AmpC β-lactamases.
AmpC is a group I class C chromosomally encoded β-
lactamase present in Ps. aeruginosa and in most Enterobacte-
riaceae 
17. In a wild-type cell, AmpC production is expressed
at constitutively low levels due to the binding of UDP-
MurNAc-pentapeptide to AmpR. Mutations associated with
AmpR and AmpD can result in AmpC overproduction, which
has been termed derepression 
17, 28, 29. Phenotypically, derep-
ressed mutants can be resistant to expanded-spectrum cephalo-
sporins, due to overproduction of AmpC 
30.
In our study the collected strains were incubated in the
presence of ceftazidime, in concentrations higher than MIC
(MIC×2 and MIC×4). In the presence of these concentrations
of ceftazidime, no colonies of the initial strains should be de-
veloped 
6, 21, 22. Nevertheless, an unexpectedly high number of
resistant strains was observed. In 20 cultures, 11 clones of re-
sistant strains of Ps. aeruginosa were developed (a total of
55%); 6 clones of resistant strains were developed in the pres-
ence of a concentration of ceftazidime equal to MIC×2 (60%)
and 5 clones of resistant strains were developed in the pres-
ence of a concentration of ceftazidime equal to MIC×4 (50%).
Table 1
Hydrolysis of cefazolin (% in 10 sec) by original strains of Pseudomonas aeruginosa and by
strains that developed resistance in the presence of concentrations of ceftazidime equal to
MIC×2 and MIC×4
Original strain of Pseu-
domonas aeruginosa
Strain developed in the presence
of ceftazidime MIC×2
Strain developed in the presence
of ceftazidime MIC×4
20 28 26
36 33 73
23 10 10
21 29 28
21 – –
25 – –
20 – –
18 – –
15 23 26
28 23 –
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This number of resistant strains seems to be extremely
high but it is consistent to the rapidity with which bacteria
produce mutants (frequency 10–5 to 10–8) 
25–27. This means
that commonly used treatments such as the currently popular
expanded spectrum 3rd generation cephalosporins are, in
turn, compromised. The consequences of this type of antibi-
otic nullification are highly important if we consider that: 1)
the clinical strains of Ps. aeruginosa, which were used, were
not only highly sensitive to ceftazidime but also multisensi-
tive to the most potent and highly effective cephalosporins,
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Fig. 1 – Hydrolysis of cefazolin by enzymes produced by the original and resistant strains of Pseudomonas aeruginosa
Hydrolysis of cefazolin was estimated by measuring the change of its absorbance on 272 nm using a Shimadzu 160A spectrophotometer.
––♦–– Hydrolysis of cefazolin by enzymes produced by the original strains of Pseudomonas aeruginosa; ---■--- hydrolysis of cefazolin by enzymes
produced by resistant strains of Pseudomonas aeruginosa, which were developed during culture in the presence of ceftazidime in concentration equal
to MIC×2; ---▲--- hydrolysis of cefazolin by enzymes produced by resistant strains of Pseudomonas aeruginosa, which were developed during
culture in the presence of ceftazidime in concentration equal to MIC×4Volumen 66, Broj 10 VOJNOSANITETSKI PREGLED Strana 789
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the strains of Ps. aeruginosa were cultivated in concentra-
tions of ceftazidime considerably higher than MIC (MIC×2
and MIC×4).
In our study seven out of eleven resistant strains pre-
sented a higher hydrolysing capacity than original strains and
four out of eleven resistant strains presented a lower hydro-
lysing capacity than original strains. This means that in four
out of eleven strains, resistance was developed by a mecha-
nism not associated with derepressed expression of chromo-
somal AmpC. Other mechanisms of developing resistance
must be implicated in these cases, like decreased permeabil-
ity and upregulation of the efflux system 
31–37.
The present findings, which were observed in our
study  in vitro, reflect also the in vivo tendency of Ps.
aeruginosa to develop resistant strains during chemother-
apy with ceftazidime, and finally the probability of thera-
peutic failure. This probability seems to be higher than
expected, and can be developed in a very short time. For-
tunately, our immune system protects us against resistant
strains developed during chemotherapy, and so, results of
this phenomenon may not be dramatic in all cases. How-
ever, in immunocompromised patients and in severely ill
patients of ICU, the danger of therapeutic failure is very
high and the risk of death is not infrequent. In fact, the
rapidity with which Ps. aeruginosa produces resistant
strains ensures that commonly used treatments such as the
currently popular antipseudomonal cephalosporin, cefta-
zidime, may be proved ineffective. Although there are
modified double-disk tests for the detection of Entero-
bacteriaceae producing basal AmpC β-lactamases 
7, there
are no recommendations for the detection of these en-
zymes in Ps. aeruginosa. On the other hand, there is no
available test to predict which strains carry inducible
AmpC enzymes 
22 or which mutations will be developed
during treatment.
Conclusion
Our study indicates that Ps. aeruginosa producing basal
AmpC β-lactamases presents a high tendency to develop re-
sistant strains after exposure to ceftazidime in vitro, regard-
less of the susceptibility test results. This tendency reflects a
similar effect in vivo, which may lead to therapeutic failure
in immunocompromised patients. In clinical practice, it is
probable that development of resistance during treatment
may occur more rapidly and more frequently than we ex-
pected. Special care should be taken for ICU patients, as the
kind of mutations that are developed during treatment cannot
be predicted.
Resistant strains that were developed in our study ex-
pressed higher cephalosporinase activity than original
strains, suggesting derepression of chromosomal β-
lactamases in most cases. Our model offers a simple, inex-
pensive and rapid method for detecting resistance of Ps.
aeruginosa due to derepression of β-lactamases, and for dis-
criminating mutants with derepressed β-lactamases from
mutants that developed other mechanisms of resistance.
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